Pages that link to "Q51911689"
Jump to navigation
Jump to search
The following pages link to Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration (Q51911689):
Displaying 50 items.
- Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism (Q22252536) (← links)
- Quetiapine in the treatment of psychosis in Parkinson's disease (Q24628941) (← links)
- Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies (Q24680260) (← links)
- The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease (Q26738456) (← links)
- Electroconvulsive therapy in Parkinson's disease (Q26786623) (← links)
- Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis (Q28074468) (← links)
- Parkinson Disease and Dementia (Q30248574) (← links)
- Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management (Q30249553) (← links)
- Treatment of psychosis and dementia in Parkinson's disease. (Q30358337) (← links)
- Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis (Q30489967) (← links)
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease (Q33607256) (← links)
- Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study (Q33810051) (← links)
- Parkinson's disease: the quintessential neuropsychiatric disorder (Q33917094) (← links)
- Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis (Q33957582) (← links)
- Review: management of Parkinson's disease (Q34332812) (← links)
- Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease (Q34388686) (← links)
- Behavioral effects of levodopa (Q34452922) (← links)
- Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis (Q34660675) (← links)
- Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines (Q34758986) (← links)
- New Wine in Old Bottle: Late-life Psychosis (Q34976609) (← links)
- An update expert opinion on management and research strategies in Parkinson's disease psychosis (Q35154278) (← links)
- Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa (Q35614156) (← links)
- Quetiapine safety in older adults: a systematic literature review. (Q35905294) (← links)
- Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. (Q35988441) (← links)
- Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications (Q36351543) (← links)
- Intervening in the neuropsychiatric features of Parkinson's disease (Q36847266) (← links)
- Management of the behavioral aspects of Parkinson's disease (Q36847271) (← links)
- Current approaches to the treatment of Parkinson's disease (Q36876438) (← links)
- Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report. (Q36932291) (← links)
- New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins (Q37021326) (← links)
- Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease (Q37039444) (← links)
- Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. (Q37087146) (← links)
- Treatment options for non-motor symptoms in late-stage Parkinson's disease (Q37098986) (← links)
- Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP) (Q37208415) (← links)
- Hallucinations in Parkinson disease (Q37508601) (← links)
- Beyond tremor and rigidity: non-motor features of Parkinson's disease (Q37579709) (← links)
- Non-motor symptoms in Parkinson's disease (Q37587798) (← links)
- Management of non-motor complications in Parkinson's disease (Q37587801) (← links)
- What do clinical trials tell us about treating patients? (Q37677188) (← links)
- Hallucinations and psychosis in Parkinson's disease (Q37685662) (← links)
- Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease (Q37722750) (← links)
- Management of hallucinations and psychosis in Parkinson's disease (Q37792384) (← links)
- Emergency presentations of Parkinson's disease: early recognition and treatment are crucial for optimum outcome (Q37812207) (← links)
- Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital (Q37862378) (← links)
- Hallucinations in neurodegenerative diseases. (Q37876971) (← links)
- Drug-induced parkinsonism in the elderly: incidence, management and prevention (Q37976411) (← links)
- Update on the medical management of Parkinson disease (Q38027352) (← links)
- Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. (Q38070888) (← links)
- Treating psychosis in movement disorder patients: a review (Q38213306) (← links)
- Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease (Q38258699) (← links)